- Human（1）
No data
- His Tag（1）
No data
- HEK293（1）
No data
- Unconjugated（1）
No data
- RUO（1）
No data
- No（1）
No data
- 20ug/$245.00
- 500ug/$2225.00
No data
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| BCHE | Human BCHE / Butyrylcholinesterase Protein, His Tag (active enzyme) |  Human | HEK293 |  | SDS-PAGE | $245.00 20ug |   |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bisnorcymserine | ANVS-301 | Phase 1 Clinical | Horizon Therapeutics PLC, National Institute On Aging (NIA) | Alzheimer Disease | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Rivastigmine Tartrate | SDZ-212-713; SDZ 212713; SDZ-ENA-713; ONO-2540; ENA-713; ENA-713D | Approved | Novartis Pharma Ag | Exelon TDS, Rivastach, Exelon MR, Prometax, Exelon, 艾斯能 | EU | Alzheimer Disease; Parkinson Disease; Dementia | Novartis Europharm Ltd | 1998-05-11 | Alzheimer Disease; Anticholinergic Syndrome; Brain Injuries, Traumatic; Cocaine-Related Disorders; Cognition Disorders; Delirium; Dementia; Dementia, Vascular; Down Syndrome; Neurobehavioral Manifestations; Parkinson Disease; Substance-Related Disorders | Details |
| Rivastigmine Twice Weekly Transdermal Patch (Luye Pharma) | LY-03013; LY-30410; RID-TDS | Approved | Acino International AG | Rivirec, 金斯明, Kingsmin, Rivalif® | Mainland China | Alzheimer Disease | Luye Pharma Group Ltd | Alzheimer Disease; Parkinson Disease | Details |
